Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment

Jeffrey A Sparks¹, Sara K Tedeschi²

Affiliations

¹ Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston 02115, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: jsparks@bwh.harvard.edu.
² Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston 02115, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

PMID: 35772415
PMCID: PMC9236564
DOI: 10.1016/S2213-2600(22)00224-7

Comment

Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment

Jeffrey A Sparks et al. Lancet Respir Med. 2022 Sep.

. 2022 Sep;10(9):813-815.

doi: 10.1016/S2213-2600(22)00224-7. Epub 2022 Jun 27.

Authors

Jeffrey A Sparks¹, Sara K Tedeschi²

Affiliations

¹ Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston 02115, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: jsparks@bwh.harvard.edu.
² Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston 02115, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

PMID: 35772415
PMCID: PMC9236564
DOI: 10.1016/S2213-2600(22)00224-7

No abstract available

PubMed Disclaimer

Conflict of interest statement

JAS reports consultancy fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, and Gilead, unrelated to this work. SKT reports consulting fees from NGM Biopharmaceuticals, unrelated to this work, and research grant payments from ModernaTx to her institution for a study of COVID-19 vaccination.

Figures

See this image and copyright information in PMC

Comment on

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
Abhishek A, Boyton RJ, Peckham N, McKnight Á, Coates LC, Bluett J, Barber V, Cureton L, Francis A, Appelbe D, Eldridge L, Julier P, Valdes AM, Brooks T, Rombach I, Altmann DM, Nguyen-Van-Tam JS, Williams HC, Cook JA; VROOM study investigators. Abhishek A, et al. Lancet Respir Med. 2022 Sep;10(9):840-850. doi: 10.1016/S2213-2600(22)00186-2. Epub 2022 Jun 27. Lancet Respir Med. 2022. PMID: 35772416 Free PMC article. Clinical Trial.

References

1. Conway R, Grimshaw AA, Konig MF, et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis Rheumatol. 2022;74:766–775. - PMC - PubMed
1. Solomon DH, Glynn RJ, Karlson EW, et al. Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med. 2020;172:369–380. - PMC - PubMed
1. Widdifield J, Kwong JC, Chen S, et al. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis. Lancet Rheumatol. 2022;4:e430–e440. - PMC - PubMed
1. Tedeschi SK, Stratton J, Ellrodt JE, et al. Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine. Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2022-222232. published online Feb 15. - DOI - PMC - PubMed
1. Haberman RH, Um S, Axelrad JE, et al. Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. Lancet Rheumatol. 2022;4:e384–e387. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment

Affiliations

Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment

Authors

Affiliations

Conflict of interest statement

Figures

Comment on

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical